Where there could be some benefit is in the reduced intensity transplant setting where EPO responsive erythroid precursor may persist following conditioning. The problem is that evidence in the shape of prospective studies is lacking.

Because of the limited number and mixed results of studies, the use of erythropoietin and G-CSF in combination is not generally accepted and experience with biosimilars is therefore lacking.

Erythropoietin may also be used to treat anaemia (haemoglobin > 10 to ≤ 13 g/dL). However, use of erythropoietin in healthy donors of stem cells to maintain haematocrit levels, is generally not allowed. The concern in this setting is that unexpected toxicity might have a detrimental effect and so the use of biosimilar epoetins for this indication is not recommended. There is no experience reported in the literature.

Conflict of interest
The author of the research paper did not declare any conflict of interest.

Editor’s comment
There is a lack of evidence for the use of biosimilar erythropoietin in the indications discussed in this paper. If you are interested in contributing a research paper in this area to GaBI Journal, please send us your submission here.

Related articles

Use of G-CSF biosimilars for reduction of fever

Use of G-CSF biosimilars for stem cell mobilization in autologous transplantation

Use of G-CSF biosimilars for stem cell mobilization in healthy donors

Reference

1.  Bosi A. Use of biosimilars in hematopoietic stem cells transplantation. Drugs and Cell Therapies in Hematology. 2013;2(1):21-6.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.